Skip to content

Withholding Feeds During Red Blood Cell Transfusion and TRAGI

The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02132819
Acronym
Tx-TRAGI
Enrollment
150
Registered
2014-05-07
Start date
2014-02-28
Completion date
2015-04-30
Last updated
2014-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Feeding During Transfusion, Necrotising Enterocolitis, Transfusion, Transfusion Related Acute Gut Injury

Keywords

transfusion, feeding, TRAGI, NEC

Brief summary

Necrotising enterocolitis (NEC) is a devastating picture that all the neonatologists are afraid of facing during the follow up of newborns. During the last years, investigators ran retrospective observational studies abut NEC developing within the 48 hours after red blood cell transfusion. In the previous studies, the incidence of transfusion associated NEC (TANEC) was found to be 20-35%.Multiple transfusions potentially cause an increased risk for retinopathy of prematurity (ROP) and NEC. Investigators have also proposed a hypothesis about transfusion related acute gut injury (TRAGI), an adverse reaction of transfusion, similar to transfusion related acute lung injury (TRALI) seen in adults.In most of the neonatology clinics, withholding feeds during transfusion is not preferred. But several recent studies show an increase in the incidence of TANEC if the newborn goes on feeding before, during and after the transfusion process, especially if it is fed with a formula. The main aim of this study is to investigate the effect of withholding feeds during transfusion, on the development of TRAGI.

Interventions

OTHERWithholding feeds

At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded

OTHERfeeding during transfusion

The feeding process will be continued during the transfusion

Sponsors

Zekai Tahir Burak Women's Health Research and Education Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
7 Days to 3 Months
Healthy volunteers
No

Inclusion criteria

* \<32 weeks of gestational age or \<1500 gr, \>7 days old premature babies. * Babies which are fed enterally well at the time of tha planning of transfusion.

Exclusion criteria

* Babies with severe sepsis signs. * Babies with severe hypoxia and asphyxia. * Babies with congenital anomaly or complex cardiac anomaly.

Design outcomes

Primary

MeasureTime frameDescription
increase in the abdominal circumferencewithin 3 days after transfusion but participants will be followed for the duration of hospital stay, an expected average of 5 weeksBell's stage 1/Suspected disease: Mild systemic disease (apnoea, bradycardia, temperature instability) Mild intestinal signs (abdominal distention, gastric residuals, bloody stools) Non-specific or normal radiological signs Bell's stage 2/Definite disease: Mild to moderate systemic signs Additional intestinal signs (absent bowel sounds, abdominal tenderness) Specific radiologic signs (pneumatosis intestinalis or portal venous air) Laboratory changes (metabolic acidosis, thrombocytopaenia) Bell's stage 3/Advanced disease: Severe systemic illness (hypotension) Additional intestinal signs (striking abdominal distention, peritonitis) Severe radiologic signs (pneumoperitoneum) Additional laboratory changes (metabolic and respiratory acidosis, disseminated intravascular coagulation)

Secondary

MeasureTime frame
increase in the amounts of gastric residual aspiratesWithin 3 days after the transfusion

Other

MeasureTime frame
occult or obvious blood in stoolwithin 1 day after transfusion

Countries

Turkey (Türkiye)

Contacts

Primary ContactSuzan Sahin, MD
suzan_balkan@yahoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026